Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX in advanced hepatocellular carcinoma
NCT01429961Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- May 2011
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegafur and oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Seoul National University Hospital. Primary endpoint: Time to progression at 2 years. Status: unknown.
02
Drugs
tegafuroxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01429961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429961.